Clinical Trial Update: Ga-68-DOTATOC -PET in the Management of Pituitary Tumours [Phase 3]

View source ↗

Summary

Phase 3 trial of Ga-68-DOTATOC-PET in pituitary tumours was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pituitary Tumours

Drugs mentioned

• Ga-68-DOTATOC (Gallium-68 DOTATOC)

Snippet

Sponsor: Göteborg University | Conditions: Pituitary Tumours | Phase 3 | Status: TERMINATED